Journal of Molecular Oncology Research

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (202) 780-3397

Short Communication - Journal of Molecular Oncology Research (2023) Volume 7, Issue 6

The role of inherited genetic mutations in cancer susceptibility

Christopher Conover *

Department of Oncology, University of Turin, Orbassano, Turin, Italy.

*Corresponding Author:
Christopher Conover
Department of Oncology, University of Turin, Orbassano, Turin, Italy

Received: 01-Nov-2023, Manuscript No. AAMOR-23-119334; Editor assigned: 02-Nov-2023, PreQC No. AAMOR-23-119334; Reviewed:16-Nov-2023, QC No. AAMOR-23-119334; Revised:22-Nov-2023, Manuscript No. AAMOR-23-119334 (R); Published:30-Nov-2023, DOI:10.35841/ aamor -7.6.202

Citation: Conover C. The role of inherited genetic mutations in cancer susceptibility. J Mol Oncol Res. 2023; 7(6):202

Visit for more related articles at Journal of Molecular Oncology Research


Cancer, a group of diseases characterized by the uncontrolled growth and spread of abnormal cells, remains a significant global health challenge. While various factors contribute to cancer development, one crucial area of study is the role of inherited genetic mutations in cancer susceptibility. Advances in genetic research have unveiled a complex interplay between our genetic makeup and the likelihood of developing certain types of cancer. Understanding these inherited mutations not only sheds light on the fundamental mechanisms driving cancer but also paves the way for targeted prevention, early detection, and personalized treatment strategies. This exploration delves into the intricate relationship between inherited genetic mutations and cancer susceptibility, offering insights into the groundbreaking discoveries transforming the landscape of oncology [1, 2].

At the core of understanding cancer susceptibility lies the intricate world of genetics. Our DNA, the genetic material within each cell, carries instructions for the body's functioning. However, mutations—changes in the DNA sequence—can disrupt these instructions, leading to abnormal cell growth and cancer. Inherited genetic mutations, also known as germline mutations, are passed down from parents to their offspring and significantly influence an individual's predisposition to certain types of cancer. Scientists have identified numerous genes associated with hereditary cancer syndromes, such as BRCA1 and BRCA2, linked to breast and ovarian cancers. These discoveries have revolutionized genetic counseling and screening programs, enabling individuals with high-risk mutations to make informed decisions about their healthcare and empowering them to take proactive measures for prevention [3, 4]

Advances in genetic testing technologies have facilitated the identification of individuals carrying inherited cancer-associated mutations. Genetic counseling and risk assessment play a pivotal role in evaluating an individual's likelihood of developing cancer based on their genetic profile. By analyzing specific genes and mutations, healthcare professionals can assess the level of risk and formulate personalized prevention plans. For instance, carriers of Lynch syndrome mutations have a higher risk of colorectal and other cancers. Early detection through regular screenings and surveillance is crucial for managing cancer susceptibility, as it allows for timely intervention and potentially life-saving treatments. Moreover, understanding the inheritance patterns of these mutations within families aids in identifying at-risk relatives, enabling comprehensive preventive strategies [5, 6 ].

The identification of inherited genetic mutations has far-reaching implications for personalized cancer treatments. In recent years, targeted therapies have emerged as a promising approach in oncology. By pinpointing specific genetic mutations driving cancer growth, researchers have developed drugs tailored to inhibit these mutated genes or their related pathways. This precision medicine approach not only enhances treatment efficacy but also minimizes side effects, improving the overall quality of life for cancer patients. For example, patients with certain mutations in the EGFR gene respond exceptionally well to targeted therapies in lung cancer treatment. By decoding the genetic basis of individual cancers, oncologists can optimize treatment regimens, leading to better outcomes and increased survival rates [7, 8].

While the progress in cancer genetics offers immense potential, it also raises ethical considerations related to genetic testing, privacy, and informed consent. Balancing the benefits of genetic information with the potential psychological and social impact on individuals and families is crucial. Moreover, ongoing research continues to unveil novel genetic mutations associated with various cancer types, expanding our understanding of cancer susceptibility. Collaborative efforts between researchers, healthcare providers, and policymakers are essential to establish guidelines and regulations that ensure the responsible use of genetic information while promoting scientific advancements. As technology evolves, integrating genomic data into routine clinical practice holds the promise of enhancing cancer prevention, diagnosis, and treatment on a broader scale [9, 10].


Inherited genetic mutations significantly influence cancer susceptibility, shaping the future of oncology through personalized prevention and treatment strategies. By unraveling the complexities of our genetic makeup, scientists and healthcare professionals are paving the way for a new era in cancer care. Genetic testing and counseling empower individuals to make informed decisions about their health, enabling proactive measures to mitigate cancer risks. The integration of genetic information into clinical practice not only enhances early detection but also opens avenues for targeted therapies, ultimately improving patient outcomes and advancing the field of oncology. As research continues to expand our knowledge of cancer genetics, ethical considerations and responsible use of genetic data remain paramount, ensuring that the benefits of these advancements are accessible to all while respecting individual rights and privacy. The ongoing collaboration between researchers, clinicians, and policymakers holds the key to harnessing the full potential of cancer genetics, offering hope to individuals and families affected by hereditary cancer predisposition


  1. Shuen AY, Foulkes WD. Inherited mutations in breast cancer genes—risk and response. J Mammary Gland Biol Neoplasia. 2011;16:3-15.
  2. Indexed at, Google Scholar, Cross Ref

  3. Etchegary H, Miller F, Delaat S, et al. Decision-making about inherited cancer risk: Exploring dimensions of genetic responsibility. J Genet Couns. 2009;18:252-64.
  4. Indexed at, Google Scholar, Cross Ref

  5. Graziano F, Humar B, Guilford P. The role of the E-cadherin gene (CDH1) in diffuse gastric cancer susceptibility: from the laboratory to clinical practice. Ann Oncol. 2003;14(12):1705-13.
  6. Indexed at, Google Scholar, Cross Ref

  7. Tavano F, Gioffreda D, Fontana A, et al. Evaluation of inherited germline mutations in cancer susceptibility genes among pancreatic cancer patients: a single-center study. J Mol Med. 2023;29(1):14.
  8. Indexed at, Google Scholar, Cross Ref

  9. Grant RC, Selander I, Connor AA, et al. Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer. Gastroenterol. 2015;148(3):556-64.
  10. Indexed at, Google Scholar, Cross Ref

  11. Damiola F, Pertesi M, Oliver J, et al. Rare key functional domain missense substitutions in MRE11A, RAD50, and NBN contribute to breast cancer susceptibility: results from a Breast Cancer Family Registry case-control mutation-screening study. Breast Cancer Res. 2014;16:1-6.
  12. Indexed at, Google Scholar, Cross Ref

  13. Kuhlen M, Borkhardt A. Cancer susceptibility syndromes in children in the area of broad clinical use of massive parallel sequencing. Eur J Pediatr. 2015;174:987-97.
  14. Indexed at, Google Scholar, Cross Ref

  15. Hedau S, Jain N, Husain SA, et al. Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India. Breast Cancer Res Treatent. 2004;88:177-86.
  16. Indexed at, Google Scholar, Cross Ref


  17. Schultz CL, Alderfer MA, Lindell RB, et al. The influence of adolescence on parents’ perspectives of testing and discussing inherited cancer predisposition. J Genet Couns. 2018;27:1395-404.
  18. Indexed at, Google Scholar, Cross Ref

  19. Crank MC, Grossman JK, Moir S, et al. Mutations in PIK3CD can cause hyper IgM syndrome (HIGM) associated with increased cancer susceptibility. J Clin Immunol. 2014;34:272-6.
  20. Indexed at, Google Scholar, Cross Ref

Get the App